Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
复制标题
DOI：
10.1182/blood-2017-05-783225
复制
发表时间：
2017-08-31
期刊：
影响因子：
20.3
通讯作者：
Verstovsek, Srdan
中科院分区：
文献类型：
--
作者：
Newberry, Kate J.;Patel, Keyur;Verstovsek, Srdan
尽管骨髓纤维化(MF)的体征和症状有了显著改善，并可能延长患者的生存时间，但一些人患有对鲁索利替尼难以治愈的疾病，许多人随着时间的推移失去了反应。此外，携带-gt；=3突变的患者对鲁索利替尼的反应较小。在这里，我们描述了在我们中心1/2期研究中登记的MF患者停用Ruxolitinib后的结果。经过79个月的中位随访，86名患者停止使用鲁索利替尼(其中30人在治疗过程中死亡)。其余56例患者停药后的中位随访期为32个月，中位生存期为14个月。血小板
Despite significant improvements in the signs and symptoms of myelofibrosis (MF), and possible prolongation of patients' survival, some have disease that is refractory to ruxolitinib and many lose their response over time. Furthermore, patients with >= 3 mutations are less likely to respond to ruxolitinib. Here we describe outcomes after ruxolitinib discontinuation in MF patients enrolled in a phase 1/2 study at our center. After a median follow-up of 79 months, 86 patients had discontinued ruxolitinib (30 of whom died while on therapy). The median follow-up after ruxolitinib discontinuation for the remaining 56 patients was 32 months, with median survival after discontinuation of 14 months. Platelets